Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P47871
UPID:
GLR_HUMAN
Alternative names:
-
Alternative UPACC:
P47871; Q2M3M5
Background:
The Glucagon receptor, a pivotal G-protein coupled receptor, orchestrates blood glucose regulation through glycogen breakdown and gluconeogenesis. It is essential for glucose homeostasis and fasting responses, activating adenylate cyclase and engaging in phosphatidylinositol-calcium signaling.
Therapeutic significance:
Linked to Mahvash disease, a disorder stemming from gene variants affecting this receptor, it presents a unique target for therapeutic intervention. Understanding the Glucagon receptor's role could unveil new strategies for managing glucose-related disorders.